Jing Wu

Jing Wu

Auto-generated profile, based on publicly available information

Jing Wu

Department of Biomedical Engineering, McGill University, Montreal, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RZRong Zhou
Rong Zhou
CSChaoji Shi
Chaoji Shi
WTWenjie Tao
Wenjie Tao
JLJiang Li
Jiang Li
JWJing Wu
Jing Wu
SSShuyang Sun
Shuyang Sun
Purpose: Unlike advances in the genomics-driven precision treatment of cutaneous melanomas, the current poor understanding of the molecular basis of mucosal melanomas (MM) has hindered such progress for MM patients. Thus, we sought to characterize the genomic landscape of MM to identify genomic alterations with prognostic and/or therapeutic implications. Experimental Design: Whole-genome sequencing (WGS) was performed on 65 MM samples, including 63 paired tumor blood samples and 2 matched lymph node metastases, with a further droplet digital PCR–based validation study of an independent MM cohort (n = 80). Guided by these molecular insights, the FDA-approved CDK4/6 inhibitor palbociclib was tested in an MM patient-derived xenograft (PDX) trial. Results: Besides the identification of well-recognized driver mutations of BRAF (3.1%), RAS family (6.2%), NF1 (7.8%), and KIT (23.1%) in MMs, our study also found that (i) mutations and amplifications in the transmembrane nucleoporin gene POM121 (30.8%) defined a patient subgroup with higher tumor proliferation rates; (ii) enrichment of structural variations between chromosomes 5 and 12 defined a patient subgroup with significantly worse clinical outcomes; (iii) over 50% of the MM patients harbored recurrent focal amplification of several oncogenes (CDK4, MDM2, and AGAP2) at 12q13-15, and this co-occurred significantly with amplification of TERT at 5p15, which was verified in the validation cohort; (iv) the PDX trial demonstrated robust antitumor effects of palbociclib in MMs harboring CDK4 amplification. Conclusions: Our largest-to-date cohort WGS analysis of MMs defines the genomic landscape of this deadly cancer at unprecedented resolution and identifies genomic aberrations that could facilitate the delivery of precision cancer treatments. See related commentary by Shoushtari, p. 3473

15 October 2017 in Stem Cells and Development
Verified
Journal Article
Open access
YWYan-Yu Wang
Yan-Yu Wang
WCWen-Lian Chen
Wen-Lian Chen
XWXiang-Qin Weng
Xiang-Qin Weng
YSYan Sheng
Yan Sheng
JWJing Wu
Jing Wu
JWJin Wang
Jin Wang
Recent reports state that C-type lectin-like molecule-1 (CLL-1) in acute myeloid leukemia (AML) is expressed primarily on myeloid cells, but there is still no investigation about its prognostic significance on leukemic blast compartment. Hence, this study aimed to evaluate the prognostic value of CLL-1 in 123 patients with de novo CD34+ Non-M3 AML. Multiparameter flow cytometry was used to assess the expression of CLL-1 on immature compartment in AML and control groups. We found that CLL-1 expression level on blast compartment was closely linked to clinical characteristics, treatment response, and survival outcome of patients. Decreased expression of CLL-1 was observed on immature compartment from AML patients as compared with controls (62.6% vs. 86.5%, P < 0.05). Logistic model exhibited that CLL-1low independently predicted low complete remission rate with an odds ratio of 4.57 (2.53–6.61, P < 0.05). Additionally, CLL-1 expression level at diagnosis was inversely correlated to the residual blast cells (residual leukemia cell) after induction chemotherapy (r = −0.423, P < 0.05). Furthermore, multivariate Cox regression model demonstrated that CLL-1low was still an independent adverse predictor (P < 0.05 for event-free survival, P < 0.05 for overall survival). Notably, CLL-1low was able to discriminate poor survival patients from intermediate- and favorable-risk groups. Taken together, CLL-1 is a novel prognostic predictor that could be exploited to supplement the current AML prognostic risk stratification system, and potentially optimize the clinical management of AML.

29 April 2026 in Nature
Verified
Journal Article
Closed access
PDF file
SJShuaibing Jiang
Shuaibing Jiang
GBGuangyu Bao
Guangyu Bao
ZYZhen Yang
Zhen Yang
JWJing Wu
Jing Wu
XYXingwei Yang
Xingwei Yang
JLJianyu Li
Jianyu Li

31 March 2023
Verified
Other
Open access
RZRong Zhou
Rong Zhou
CSChaoji Shi
Chaoji Shi
WTWenjie Tao
Wenjie Tao
JLJiang Li
Jiang Li
JWJing Wu
Jing Wu
SSShuyang Sun
Shuyang Sun
Significantly mutated genes,promoters and UTRs of MMs.

31 March 2023
Verified
Other
Open access
RZRong Zhou
Rong Zhou
CSChaoji Shi
Chaoji Shi
WTWenjie Tao
Wenjie Tao
JLJiang Li
Jiang Li
JWJing Wu
Jing Wu
SSShuyang Sun
Shuyang Sun
Purpose:Unlike advances in the genomics-driven precision treatment of cutaneous melanomas, the current poor understanding of the molecular basis of mucosal melanomas (MM) has hindered such progress for MM patients. Thus, we sought to characterize the genomic landscape of MM to identify genomic alterations with prognostic and/or therapeutic implications.Experimental Design:Whole-genome sequencing (WGS) was performed on 65 MM samples, including 63 paired tumor blood samples and 2 matched lymph node metastases, with a further droplet digital PCR–based validation study of an independent MM cohort (n = 80). Guided by these molecular insights, the FDA-approved CDK4/6 inhibitor palbociclib was tested in an MM patient-derived xenograft (PDX) trial.Results:Besides the identification of well-recognized driver mutations of BRAF (3.1%), RAS family (6.2%), NF1 (7.8%), and KIT (23.1%) in MMs, our study also found that (i) mutations and amplifications in the transmembrane nucleoporin gene POM121 (30.8%) defined a patient subgroup with higher tumor proliferation rates; (ii) enrichment of structural variations between chromosomes 5 and 12 defined a patient subgroup with significantly worse clinical outcomes; (iii) over 50% of the MM patients harbored recurrent focal amplification of several oncogenes (CDK4, MDM2, and AGAP2) at 12q13-15, and this co-occurred significantly with amplification of TERT at 5p15, which was verified in the validation cohort; (iv) the PDX trial demonstrated robust antitumor effects of palbociclib in MMs harboring CDK4 amplification.Conclusions:Our largest-to-date cohort WGS analysis of MMs defines the genomic landscape of this deadly cancer at unprecedented resolution and identifies genomic aberrations that could facilitate the delivery of precision cancer treatments.See related commentary by Shoushtari, p. 3473

31 March 2023
Verified
Other
Open access
RZRong Zhou
Rong Zhou
CSChaoji Shi
Chaoji Shi
WTWenjie Tao
Wenjie Tao
JLJiang Li
Jiang Li
JWJing Wu
Jing Wu
SSShuyang Sun
Shuyang Sun
Pathway analysis in MM and comparison between MM and CM.